scorecardresearchSequent Scientific Share Price Live NSE, BSE, Today - Sequent Scientific
Mintgenie
Asian Paints2,808.45-6.30 (-0.22%)
Axis Bank1,029.505.35 (0.52%)
Bajaj Finance7,107.00217.75 (3.16%)
Bajaj Finserv1,619.6025.35 (1.59%)
Bharti Airtel1,289.3022.10 (1.74%)
HCL Technologies1,450.00-17.65 (-1.20%)
HDFC Bank1,531.3036.70 (2.46%)
Hindustan Unilever2,232.2517.30 (0.78%)
ICICI Bank1,066.4010.95 (1.04%)
ITC424.805.85 (1.40%)
Indusind Bank1,485.8011.85 (0.80%)
Infosys1,411.60-8.95 (-0.63%)
Kotak Mahindra Bank1,790.003.55 (0.20%)
Larsen & Toubro3,519.25-31.70 (-0.89%)
Mahindra & Mahindra2,082.9058.75 (2.90%)
Maruti Suzuki India12,669.35273.05 (2.20%)
NTPC350.90-0.50 (-0.14%)
Nestle India2,437.10-25.65 (-1.04%)
Power Grid Corporation Of India281.701.50 (0.54%)
Reliance Industries2,941.6013.45 (0.46%)
State Bank Of India750.806.00 (0.81%)
Sun Pharmaceutical Industries1,525.007.85 (0.52%)
Tata Consultancy Services3,827.45-36.05 (-0.93%)
Tata Motors963.20-8.20 (-0.84%)
Tata Steel162.102.10 (1.31%)
Tech Mahindra1,193.7513.90 (1.18%)
Titan Company3,563.8037.40 (1.06%)
Ultratech Cement9,399.1011.90 (0.13%)
Wipro452.858.55 (1.92%)

Sequent Scientific

BSE: 512529 | NSE: SEQUENT | ISIN: INE807F01027 | SECTOR: Biotechnology & Drugs

₹119.40 0.00 (0%)

19 Apr 2024, 09:59 (IST)

  • Open

    119.10

  • High

    119.90

  • Low

    116.45

  • Prev Close

    119.40

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    29.74B

  • Volume

    121.28K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    119.40

  • Ask

    -
View all metrics

Company Description

  • Biotechnology & Drugs

  • BSE

    512529

  • NSE

    SEQUENT

  • ISIN

    INE807F01027

SeQuent Scientific Limited is an India-based animal health company. The Company provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The Company operates through the pharmaceuticals segment. The Company is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. Its subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.

Company Officers

  • Rajaram Narayanan

    Chief Executive Officer, Managing Director, Executive Director

  • Saurav Bhala

    Chief Financial Officer

  • Phillip Trott

    Compliance Officer, Company Secretary

  • Prasad Lad

    Vice President-Human Resources & Admin

  • Sharat Narasapur

    Joint Managing Director, Executive Director

  • Vedprakash Ragate

    Additional Executive and Non-Independent Director

  • Yawar Abbas

    Emerging markets

  • Jose Filho

    Latin America Operations

  • Alexis Goux

    Global Formulations

  • Ashish Kakabalia

    Business Development and R&D